Arrowhead Pharmaceuticals

ARWR49

$19.41arrow_drop_up3.29%$0.62

ARWR49

$19.41

arrow_drop_up3.29%$0.62

Performance History

Key Stats
Open	$19.20
Prev. Close	$18.79
EPS	-4.65
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	19.20	19.41
52 Week Range	18.03	39.83

Ratios







EPS	-4.65

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Arrowhead Pharmaceuticals (ARWR)

Arrowhead Pharmaceuticals Inc. (ARWR) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. The company specializes in the discovery and development of RNAi-based drugs that target and silence specific genes involved in various diseases. Arrowhead's proprietary technology platform, called Dynamic Polyconjugates (DPCs), allows for the efficient delivery of RNAi molecules to specific tissues, enabling targeted gene silencing and disease modification. The company's pipeline includes multiple clinical-stage candidates targeting different indications, such as liver diseases, cardio-metabolic disorders, and various oncology indications.

Arrowhead Pharmaceuticals Inc. (ARWR) quote: ARWR is currently trading at $75.20 per share. The stock has a market capitalization of $8.5 billion. Over the past year, ARWR has experienced significant growth, with a 52-week range of $23.46 to $88.20. As of today, the stock is trading near its 52-week high. The trading volume for ARWR is relatively high, indicating strong investor interest. The PEG ratio for ARWR is not currently available. When comparing ARWR to its industry peers, the stock has outperformed with its strong growth trajectory. Arrowhead Pharmaceuticals Inc. is well-positioned in the RNAi therapeutics space.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Christopher R. Anzalone Ph.D.
Headquarters: Pasadena
Employees: 397
Exchange: NASDAQ

add Arrowhead Pharmaceuticals to watchlist

Keep an eye on Arrowhead Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Arrowhead Pharmaceuticals 's (ARWR) price per share?

The current price per share for Arrowhead Pharmaceuticals (ARWR) is $19.41. The stock has seen a price change of $0.62 recently, indicating a 3.3% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Arrowhead Pharmaceuticals (ARWR)?

For Arrowhead Pharmaceuticals (ARWR), the 52-week high is $39.83, which is 105.2% from the current price. The 52-week low is $18.04, the current price is 7.6% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Arrowhead Pharmaceuticals (ARWR) a growth stock?

Arrowhead Pharmaceuticals (ARWR) has shown an average price growth of -3.36% over the past three years. It has received a score of 13 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Arrowhead Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Arrowhead Pharmaceuticals (ARWR) stock price performance year to date (YTD)?

As of the latest data, Arrowhead Pharmaceuticals (ARWR) has a year-to-date price change of -37.41%. Over the past month, the stock has experienced a price change of -3.43%. Over the last three months, the change has been -21.42%. Over the past six months, the figure is -18.85%. Looking at a longer horizon, the five-year price change stands at -65.94%.

help

Is Arrowhead Pharmaceuticals (ARWR) a profitable company?

Arrowhead Pharmaceuticals (ARWR) has a net income of -$209.28M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -2.79K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $240.74M, although specific revenue growth data is currently not available. The gross profit is $240.74M. Operating income is noted at -$205M. Furthermore, the EBITDA is -$529.78M.

help

What is the market capitalization of Arrowhead Pharmaceuticals (ARWR)?

Arrowhead Pharmaceuticals (ARWR) has a market capitalization of $2.33B. The average daily trading volume is 19.4, indicating the stock's liquidity and investor engagement.